Goldenberg pioneered the development of radiolabeled antibodies for various applications in the detection, diagnosis and therapy of cancer. Under his leadership, the scientists and clinicians at the Garden State Cancer Center have developed antibodies for the diagnosis, detection and treatment of solid tumors such as colorectal, pancreatic, lung, breast and ovarian cancers, as well as certain hematologic cancers such as lymphoma and multiple myeloma. He has overseen the in-house clinic as well as clinical outreach at affiliated institutions in the United States and Europe for treatment of cancer patients with radiolabeled antibodies. He also helped develop two diagnostic radiopharmaceuticals marketed by Immunomedics Inc., which he established in 1982.
Goldenberg, who has been in his current position at the Garden State Cancer Center since 1990, is also the president and chief executive officer of CMMI, a not-for-profit, independent, specialized research center he formed in 1982; the center focuses on the development of biological strategies to detect and treat cancer and immunological diseases. Over the past 30 years, this distinguished scientist has been a major contributor to the current knowledge of the basic principles of the preparation and utilization of radioimmunoconjugates in medical diagnosis, including functional imaging and guided radionuclide therapy. Goldenberg, who has published more than 500 articles in peer-reviewed journals, is currently exploring the use of positron emission tomography (PET) tracers in immunodiagnosis and therapy, especially by pretarge
'"/>
Contact: Maryann Verrillo
mverrillo@snm.org
703-708-9000
Society of Nuclear Medicine
19-Jun-2005